{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T10:40:34Z","timestamp":1795084834045,"version":"4.10.2"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2021,4,22]],"date-time":"2021-04-22T00:00:00Z","timestamp":1619049600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,4,22]],"date-time":"2021-04-22T00:00:00Z","timestamp":1619049600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100012681","name":"Universit\u00e4tsklinikum K\u00f6ln","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100012681","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Head and Neck Pathol"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Treatment options for unresectable, recurrent or metastatic salivary gland carcinomas (SGC) are scarce. Trophoblast cell surface antigen 2 (Trop-2) is a transmembrane glycoprotein that is involved in a variety of oncogenic cell signaling pathways. Its potential as a target for the antibody\u2013drug conjugate sacituzumab govitecan has already been demonstrated in different tumor entities. The United States Food and Drug Administration approved this antibody\u2013drug conjugate for the treatment of metastatic triple-negative breast cancer. Here, we aimed to investigate Trop-2 protein expression in different entities of SGCs. We retrospectively reviewed the medical records of all patients that underwent surgery for a primary SGC in a tertiary referral center between 1990 and 2014. Immunohistochemical (IHC) staining for Trop-2 was performed and rated as negative, weak, moderate or high using a semiquantitative score. Additionally, representative cases were analyzed using MALDI-mass spectrometry (MS) imaging to confirm the IHC results. The cohort consisted of 114 tumors of the parotid gland (90.4%) and submandibular gland (9.6%). It mainly included mucoepidermoid, salivary duct and adenoid cystic carcinomas. In IHC samples, 44% showed high, 38% moderate and 10% weak expression rates of Trop-2. MALDI-MS imaging confirmed the presence of Trop-2 protein in 80% of the tested tumor samples. This is the first study to demonstrate that several types of SGC express Trop-2 with variable intensity. Since there are currently few systemic treatment options for advanced SGCs, Trop-2 represents a promising target for further clinical studies, for instance, with sacituzumab govitecan.<\/jats:p>","DOI":"10.1007\/s12105-021-01325-5","type":"journal-article","created":{"date-parts":[[2021,4,22]],"date-time":"2021-04-22T08:03:30Z","timestamp":1619078610000},"page":"1147-1155","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Trophoblast Cell Surface Antigen 2 (Trop-2) Protein is Highly Expressed in Salivary Gland Carcinomas and Represents a Potential Therapeutic Target"],"prefix":"10.1007","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9019-2840","authenticated-orcid":false,"given":"Philipp","family":"Wolber","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Nachtsheim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franziska","family":"Hoffmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens Peter","family":"Klu\u00dfmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moritz","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ferdinand","family":"von Eggeling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orlando","family":"Guntinas-Lichius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Quaas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Arolt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,4,22]]},"reference":[{"key":"1325_CR1","doi-asserted-by":"publisher","first-page":"4123","DOI":"10.18632\/oncotarget.27797","volume":"11","author":"J Meinrath","year":"2020","unstructured":"Meinrath J, Haak A, Igci N, Dalvi P, Arolt C, Meemboor S, et al. Expression profiling on subclasses of primary parotid gland carcinomas. Oncotarget. 2020;11:4123\u201337.","journal-title":"Oncotarget"},{"key":"1325_CR2","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.path.2016.11.004","volume":"10","author":"RR Seethala","year":"2017","unstructured":"Seethala RR. Salivary gland tumors: current concepts and controversies. Surg Pathol Clin. 2017;10:155\u201376.","journal-title":"Surg Pathol Clin."},{"key":"1325_CR3","first-page":"606","volume":"49","author":"M Westergaard-Nielsen","year":"2020","unstructured":"Westergaard-Nielsen M, Rosenberg T, Gerke O, Dyrvig A-K, Godballe C, Bj\u00f8rndal K. Elective neck dissection in patients with salivary gland carcinoma: a systematic review and meta-analysis. J Oral Pathol Med Off Publ Int Assoc Oral Pathol Am Acad Oral Pathol. 2020;49:606\u201316.","journal-title":"J Oral Pathol Med Off Publ Int Assoc Oral Pathol Am Acad Oral Pathol."},{"key":"1325_CR4","doi-asserted-by":"publisher","first-page":"S52","DOI":"10.1016\/j.ijrobp.2007.04.079","volume":"69","author":"CHJ Terhaard","year":"2007","unstructured":"Terhaard CHJ. Postoperative and primary radiotherapy for salivary gland carcinomas: indications, techniques, and results. Int J Radiat Oncol Biol Phys. 2007;69:S52-55.","journal-title":"Int J Radiat Oncol Biol Phys."},{"key":"1325_CR5","doi-asserted-by":"publisher","first-page":"2057","DOI":"10.1002\/lary.26516","volume":"127","author":"A Lee","year":"2017","unstructured":"Lee A, Givi B, Osborn VW, Schwartz D, Schreiber D. Patterns of care and survival of adjuvant radiation for major salivary adenoid cystic carcinoma. Laryngoscope. 2017;127:2057\u201362.","journal-title":"Laryngoscope"},{"key":"1325_CR6","doi-asserted-by":"publisher","first-page":"572493","DOI":"10.3389\/fonc.2020.572493","volume":"10","author":"W Hu","year":"2020","unstructured":"Hu W, Hu J, Huang Q, Gao J, Yang J, Qiu X, et al. Particle beam radiation therapy for adenoid cystic carcinoma of the nasal cavity and paranasal sinuses. Front Oncol. 2020;10:572493.","journal-title":"Front Oncol."},{"key":"1325_CR7","doi-asserted-by":"publisher","first-page":"S142","DOI":"10.1017\/S0022215116000566","volume":"130","author":"S Sood","year":"2016","unstructured":"Sood S, McGurk M, Vaz F. Management of Salivary Gland Tumours: United Kingdom National Multidisciplinary Guidelines. J Laryngol Otol. 2016;130:S142\u20139.","journal-title":"J Laryngol Otol"},{"key":"1325_CR8","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.radonc.2017.04.026","volume":"123","author":"H Ikawa","year":"2017","unstructured":"Ikawa H, Koto M, Takagi R, Ebner DK, Hasegawa A, Naganawa K, et al. Prognostic factors of adenoid cystic carcinoma of the head and neck in carbon-ion radiotherapy: The impact of histological subtypes. Radiother Oncol J Eur Soc Ther Radiol Oncol. 2017;123:387\u201393.","journal-title":"Radiother Oncol J Eur Soc Ther Radiol Oncol"},{"key":"1325_CR9","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1080\/00016489.2017.1371329","volume":"138","author":"S Takebayashi","year":"2018","unstructured":"Takebayashi S, Shinohara S, Tamaki H, Tateya I, Kitamura M, Mizuta M, et al. Adenoid cystic carcinoma of the head and neck: a retrospective multicenter study. Acta Otolaryngol (Stockh). 2018;138:73\u20139.","journal-title":"Acta Otolaryngol (Stockh)"},{"key":"1325_CR10","doi-asserted-by":"publisher","first-page":"3946","DOI":"10.18632\/oncotarget.13952","volume":"8","author":"X Wang","year":"2017","unstructured":"Wang X, Luo Y, Li M, Yan H, Sun M, Fan T. Management of salivary gland carcinomas - a review. Oncotarget. 2017;8:3946\u201356.","journal-title":"Oncotarget"},{"key":"1325_CR11","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.anorl.2015.09.009","volume":"133","author":"M Meyers","year":"2016","unstructured":"Meyers M, Granger B, Herman P, Janot F, Garrel R, Fakhry N, et al. Head and neck adenoid cystic carcinoma: A prospective multicenter REFCOR study of 95 cases. Eur Ann Otorhinolaryngol Head Neck Dis. 2016;133:13\u20137.","journal-title":"Eur Ann Otorhinolaryngol Head Neck Dis"},{"key":"1325_CR12","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1002\/lary.20684","volume":"120","author":"A Oplatek","year":"2010","unstructured":"Oplatek A, Ozer E, Agrawal A, Bapna S, Schuller DE. Patterns of recurrence and survival of head and neck adenoid cystic carcinoma after definitive resection. Laryngoscope. 2010;120:65\u201370.","journal-title":"Laryngoscope"},{"key":"1325_CR13","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1016\/j.ijrobp.2006.06.050","volume":"66","author":"AM Chen","year":"2006","unstructured":"Chen AM, Bucci MK, Quivey JM, Garcia J, Eisele DW, Fu KK. Long-term outcome of patients treated by radiation therapy alone for salivary gland carcinomas. Int J Radiat Oncol Biol Phys. 2006;66:1044\u201350.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1325_CR14","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s13014-016-0617-7","volume":"11","author":"C-E Hsieh","year":"2016","unstructured":"Hsieh C-E, Lin C-Y, Lee L-Y, Yang L-Y, Wang C-C, Wang H-M, et al. Adding concurrent chemotherapy to postoperative radiotherapy improves locoregional control but Not overall survival in patients with salivary gland adenoid cystic carcinoma-a propensity score matched study. Radiat Oncol Lond Engl. 2016;11:47.","journal-title":"Radiat Oncol Lond Engl"},{"key":"1325_CR15","first-page":"113","volume":"37","author":"A Mousa","year":"2016","unstructured":"Mousa A, Rahimi K, Warkus T. Neoadjuvant chemoradiotherapy followed by radical vulvectomy for adenoid cystic carcinoma of Bartholin\u2019s gland: a case report and review of the literature. Eur J Gynaecol Oncol. 2016;37:113\u20136.","journal-title":"Eur J Gynaecol Oncol"},{"key":"1325_CR16","first-page":"19","volume":"14","author":"SY Jang","year":"2014","unstructured":"Jang SY, Kim DJ, Kim CY, Wu CZ, Yoon JS, Lee SY. Neoadjuvant intra-arterial chemotherapy in patients with primary lacrimal adenoid cystic carcinoma. Cancer Imaging Off Publ Int Cancer Imaging Soc. 2014;14:19.","journal-title":"Cancer Imaging Off Publ Int Cancer Imaging Soc"},{"key":"1325_CR17","doi-asserted-by":"publisher","first-page":"84","DOI":"10.18632\/genesandcancer.40","volume":"6","author":"A Shvartsur","year":"2015","unstructured":"Shvartsur A, Bonavida B. Trop2 and its overexpression in cancers: regulation and clinical\/therapeutic implications. Genes Cancer. 2015;6:84\u2013105.","journal-title":"Genes Cancer"},{"key":"1325_CR18","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.oraloncology.2016.12.016","volume":"66","author":"S Alfieri","year":"2017","unstructured":"Alfieri S, Granata R, Bergamini C, Resteghini C, Bossi P, Licitra LF, et al. Systemic therapy in metastatic salivary gland carcinomas: A pathology-driven paradigm? Oral Oncol. 2017;66:58\u201363.","journal-title":"Oral Oncol"},{"key":"1325_CR19","doi-asserted-by":"crossref","unstructured":"Seethala RR, Stenman G. Update from the 4th Edition of the World Health Organization Classification of Head and Neck Tumours: Tumors of the Salivary Gland. Head Neck Pathol. 2017;11:55\u201367.","DOI":"10.1007\/s12105-017-0795-0"},{"key":"1325_CR20","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.oraloncology.2017.09.008","volume":"74","author":"NC Schmitt","year":"2017","unstructured":"Schmitt NC, Kang H, Sharma A. Salivary duct carcinoma: An aggressive salivary gland malignancy with opportunities for targeted therapy. Oral Oncol. 2017;74:40\u20138.","journal-title":"Oral Oncol"},{"key":"1325_CR21","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/S1470-2045(19)30856-3","volume":"21","author":"DS Hong","year":"2020","unstructured":"Hong DS, DuBois SG, Kummar S, Farago AF, Albert CM, Rohrberg KS, et al. Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1\/2 clinical trials. Lancet Oncol. 2020;21:531\u201340.","journal-title":"Lancet Oncol"},{"key":"1325_CR22","first-page":"111","volume":"11","author":"T Gibo","year":"2019","unstructured":"Gibo T, Sekiguchi N, Gomi D, Noguchi T, Fukushima T, Kobayashi T, et al. Targeted therapy with trastuzumab for epidermal growth factor receptor 2 (HER2)-positive advanced salivary duct carcinoma: A case report. Mol Clin Oncol. 2019;11:111\u20135.","journal-title":"Mol Clin Oncol"},{"key":"1325_CR23","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.2147\/OTT.S162447","volume":"12","author":"S Zaman","year":"2019","unstructured":"Zaman S, Jadid H, Denson AC, Gray JE. Targeting Trop-2 in solid tumors: future prospects. OncoTargets Ther. 2019;12:1781\u201390.","journal-title":"OncoTargets Ther"},{"key":"1325_CR24","doi-asserted-by":"publisher","first-page":"33658","DOI":"10.1038\/srep33658","volume":"6","author":"P Zeng","year":"2016","unstructured":"Zeng P, Chen M-B, Zhou L-N, Tang M, Liu C-Y, Lu P-H. Impact of TROP2 expression on prognosis in solid tumors: A Systematic Review and Meta-analysis. Sci Rep. 2016;6:33658.","journal-title":"Sci Rep"},{"key":"1325_CR25","doi-asserted-by":"publisher","first-page":"5711","DOI":"10.1158\/1078-0432.CCR-17-0933","volume":"23","author":"JE Gray","year":"2017","unstructured":"Gray JE, Heist RS, Starodub AN, Camidge DR, Kio EA, Masters GA, et al. Therapy of Small Cell Lung Cancer (SCLC) with a Topoisomerase-I-inhibiting Antibody-Drug Conjugate (ADC) Targeting Trop-2, Sacituzumab Govitecan. Clin Cancer Res Off J Am Assoc Cancer Res. 2017;23:5711\u20139.","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"1325_CR26","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1056\/NEJMoa1814213","volume":"380","author":"A Bardia","year":"2019","unstructured":"Bardia A, Mayer IA, Vahdat LT, Tolaney SM, Isakoff SJ, Diamond JR, et al. Sacituzumab govitecan-hziy in refractory metastatic triple-negative breast cancer. N Engl J Med. 2019;380:741\u201351.","journal-title":"N Engl J Med"},{"key":"1325_CR27","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1021\/acs.bioconjchem.5b00223","volume":"26","author":"TM Cardillo","year":"2015","unstructured":"Cardillo TM, Govindan SV, Sharkey RM, Trisal P, Arrojo R, Liu D, et al. Sacituzumab govitecan (IMMU-132), an Anti-Trop-2\/SN-38 antibody-drug conjugate: characterization and efficacy in pancreatic, gastric, and other cancers. Bioconjug Chem. 2015;26:919\u201331.","journal-title":"Bioconjug Chem"},{"key":"1325_CR28","doi-asserted-by":"publisher","first-page":"22496","DOI":"10.18632\/oncotarget.4318","volume":"6","author":"DM Goldenberg","year":"2015","unstructured":"Goldenberg DM, Cardillo TM, Govindan SV, Rossi EA, Sharkey RM. Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC). Oncotarget. 2015;6:22496\u2013512.","journal-title":"Oncotarget"},{"key":"1325_CR29","doi-asserted-by":"publisher","first-page":"175883592091757","DOI":"10.1177\/1758835920917571","volume":"12","author":"V Moentenich","year":"2020","unstructured":"Moentenich V, Comut E, Gebauer F, Tuchscherer A, Bruns C, Schroeder W, et al. Mesothelin expression in esophageal adenocarcinoma and squamous cell carcinoma and its possible impact on future treatment strategies. Ther Adv Med Oncol. 2020;12:1758835920917571.","journal-title":"Ther Adv Med Oncol"},{"key":"1325_CR30","doi-asserted-by":"crossref","unstructured":"Arolt C, Meyer M, Hoffmann F, Wagener-Ryczek S, Schwarz D, Nachtsheim L, et al. Expression Profiling of Extracellular Matrix Genes Reveals Global and Entity-Specific Characteristics in Adenoid Cystic, Mucoepidermoid and Salivary Duct Carcinomas. Cancers. 2020;12.","DOI":"10.3390\/cancers12092466"},{"key":"1325_CR31","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.bbagrm.2011.09.004","volume":"1819","author":"C-Y Koo","year":"2012","unstructured":"Koo C-Y, Muir KW. Lam EW-F. FOXM1: From cancer initiation to progression and treatment. Biochim Biophys Acta. 2012;1819:28\u201337.","journal-title":"Biochim Biophys Acta."},{"key":"1325_CR32","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1186\/1476-4598-9-253","volume":"9","author":"R Cubas","year":"2010","unstructured":"Cubas R, Zhang S, Li M, Chen C, Yao Q. Trop2 expression contributes to tumor pathogenesis by activating the ERK MAPK pathway. Mol Cancer. 2010;9:253.","journal-title":"Mol Cancer"},{"key":"1325_CR33","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1007\/s10637-018-0560-6","volume":"36","author":"GT King","year":"2018","unstructured":"King GT, Eaton KD, Beagle BR, Zopf CJ, Wong GY, Krupka HI, et al. A phase 1, dose-escalation study of PF-06664178, an anti-Trop-2\/Aur0101 antibody-drug conjugate in patients with advanced or metastatic solid tumors. Invest New Drugs. 2018;36:836\u201347.","journal-title":"Invest New Drugs"},{"key":"1325_CR34","doi-asserted-by":"publisher","first-page":"e75","DOI":"10.1016\/j.clgc.2015.10.002","volume":"14","author":"B Faltas","year":"2016","unstructured":"Faltas B, Goldenberg DM, Ocean AJ, Govindan SV, Wilhelm F, Sharkey RM, et al. Sacituzumab govitecan, a novel antibody-drug conjugate, in patients with metastatic platinum-resistant urothelial carcinoma. Clin Genitourin Cancer. 2016;14:e75-79.","journal-title":"Clin Genitourin Cancer"},{"key":"1325_CR35","doi-asserted-by":"publisher","first-page":"2790","DOI":"10.1200\/JCO.2016.72.1894","volume":"35","author":"RS Heist","year":"2017","unstructured":"Heist RS, Guarino MJ, Masters G, Purcell WT, Starodub AN, Horn L, et al. Therapy of advanced non-small-cell lung cancer with an SN-38-Anti-Trop-2 drug conjugate, sacituzumab govitecan. J Clin Oncol Off J Am Soc Clin Oncol. 2017;35:2790\u20137.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"1325_CR36","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1016\/S1470-2045(17)30111-0","volume":"18","author":"PC Thuss-Patience","year":"2017","unstructured":"Thuss-Patience PC, Shah MA, Ohtsu A, Van Cutsem E, Ajani JA, Castro H, et al. Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2\/3 study. Lancet Oncol. 2017;18:640\u201353.","journal-title":"Lancet Oncol"}],"container-title":["Head and Neck Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12105-021-01325-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12105-021-01325-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12105-021-01325-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T01:40:20Z","timestamp":1638322820000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12105-021-01325-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,22]]},"references-count":36,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1325"],"URL":"https:\/\/doi.org\/10.1007\/s12105-021-01325-5","relation":{},"ISSN":["1936-0568"],"issn-type":[{"value":"1936-0568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,22]]},"assertion":[{"value":"23 November 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This research study was conducted retrospectively from data obtained for clinical purposes. We consulted with the IRB of the University of Cologne who determined that our study did not need ethical approval.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}